

DEPARTMENT OF HUMAN SERVICES
Pharmacy & Therapeutics Committee Minutes
May 17, 2017

Committee Members Present:

Cheston Berlin, Jr., M.D.	Pediatrician
Gene Bishop, M.D.	Internist/Consumer Advocate
Terri Cathers, Pharm.D., Chair	OMAP Pharmacy Director
Jessica Daw, Pharm.D.	UPMC For You Pharmacist
Donald Gerhart, R.Ph.	Community Pharmacist
Heather Gross, Pharm.D.	Aetna Clinical Pharmacist
David Haverstick, M.D.	Family Practitioner
David Kelley, M.D.	OMAP Chief Medical Officer
Jaymie Lako, R.Ph.	Gateway Health Plan Pharmacist
Joshua Liao, M.D.	Internist
Andrew Maiorini, Pharm.D.	Keystone/AmeriHealth Perform Rx Clinical Pharmacist
Michele Musheno, R.Ph., M.S.	Academic/ Hospital Pharmacist
Ian Paul, M.D.	Pediatrician
James Schuster, M.D., Vice Chair	Psychiatrist
Kevin Szczecina, R.Ph.	Geisinger Health Plan Pharmacist
Andreas Wali, M.D.	Cardiologist
Lloyd Wertz	Consumer/Family Advocate
Matthew Zimmerman, Pharm.D.	Health Partners of Philadelphia Pharmacist

Committee Members Not Present:

Ivonne Acrich, M.D.	Ad Hoc Child/Adolescent Psychiatrist
Dale Adair, M.D.	OMHSAS Acting Chief Medical Officer
Andrea Fox, M.D.	Internist
James Hancovsky, R.Ph., MBA	United Health Care Pharmacy Director
Rosemary Keffer, M.D.	Ad Hoc Adult Psychiatrist

Public Testimony Heard by the Committee:

Paul Amato (ViiV) - Triumeq
Edward Casey (Pfizer) - Embeda
Domenic Montella (Novartis) - Entresto
Bruce Wallace (Silvergate) – Qbrelis, Epaned
Michael Witmer (PSU Hershey Medical Center) - Triumeq

Welcome and Introduction	Dr. Terri Cathers welcomed the Committee and the members introduced themselves.
Approval of November 2016 Minutes	The Committee approved the minutes from the November 2016 meeting without revision.
Drug Class Reviews, Public Testimony, Discussion and Voting:	
Acne Agents, Topical	The Committee reviewed the Acne Agents, Topical class and unanimously approved the following: Veltin Gel, Onexton Gel w/pump, Acanya Gel w/pump and Benzaclin Gel w/pump moving to Preferred status and Erythromycin-Benzoyl Peroxide Gel, Aczone Gel w/pump, Duac Gel, Clindamycin-Benzoyl Peroxide Gel w/pump and Clindamycin-Tretinoin gel to Non-Preferred status.
Analgesics, Opioids Long Acting	The Committee reviewed and discussed the Analgesics, Opioids Long Acting class and unanimously approved the following changes: Kadian ER 40 mg and 200 mg and Embeda (all strengths) to Preferred status and Xtampza ER to Non-Preferred status. <u>Post Meeting Note:</u> After further financial analysis, the Department recommended maintaining Non-preferred status for Kadian 40mg and 200mg. The Department also recommends changing Kadian 80 mg to Non-preferred status. The Department has identified that equivalent doses can be administered at a significantly lower cost to the Department by utilizing Embeda.
Analgesics, Opioids Short Acting	The Committee reviewed the Analgesics, Opioids Short Acting class and unanimously approved the following: moving Ibudone Tablets and Hydromorphone Tablets to Non-Preferred status.
Angiotensin Modulators	The Committee reviewed the Angiotensin Modulators class and unanimously approved the following: moving Entresto to Preferred status and Olmesartan, Olmesartan-HCTZ, Benicar, Benicar HCT, and Qbrelis to Non-Preferred status. The Committee also recommended allowing claims for non-preferred Qbrelis and Epaned liquid formulations to pay without a prior authorization for children under 9 years of age for Qbrelis and under 6 years of age for Epaned.
Angiotensin Modulator Combinations	The Committee reviewed the Angiotensin Modulator Combinations class and unanimously approved the following: moving Amlodipine-Valsartan, Amlodipine-Olmesartan and Amlodipine-Valsartan-HCTZ to Preferred status and moving Azor, Exforge, Byvalson, Telmisartan-Amlodipine and Olmesartan-Amlodipine-HCTZ to Non-Preferred status.
Antibiotics, Vaginal	The Committee reviewed the Antibiotics, Vaginal class and unanimously approved the following: moving Clindesse Cream to Preferred status.
Antifungals, Topical	The Committee reviewed the Antifungals, Topical class and unanimously approved the following: moving Nystatin Powder to Preferred status and moving Ketoconazole Foam and Oxiconazole Nitrate Cream to Non-Preferred status.
Antimigraine Agents, Triptans	The Committee reviewed the Antimigraine Agents, Triptans class and unanimously approved the following: moving Sumatriptan Pen Injector to Preferred status and moving Relpax, Onzetra Xsail, Imitrex Pen Injector, Frovatriptan Tablet and Zembrace Symtouch to Non-Preferred status.
Antiparasitics, Topical	The Committee reviewed the Antiparasitics, Topical class and unanimously approved the following: moving Sklice to Preferred status.

Antipsoriatics, Topical	The Committee reviewed the Antipsoriatics, Topical class and unanimously approved the following: moving Calcipotriene-Betamethasone DP Ointment to Non-Preferred status.
Antivirals, Oral	The Committee reviewed the Antivirals, Oral class and unanimously approved the following: moving Oseltamivir Capsules to Non-Preferred status. The brand alternative, Tamiflu, is a more cost effective alternative to the Department and is Preferred.
Beta-Blockers	The Committee reviewed the Beta-Blockers class and unanimously approved the following: moving Pindolol, Propranolol-HCTZ, and Bisoprolol to Preferred status and moving Inderal LA Capsules to Non-Preferred status.
Bladder Relaxant Preparations	The Committee reviewed the Bladder Relaxant Preparations class and unanimously approved the following: moving Toviaz to Preferred status and moving Darifenacin ER to Non-Preferred status.
Bone Resorption Suppression and Related Agents	The Committee reviewed the Bone Resorption Suppression and Related Agents class and approved the following changes: Zoledronic Acid IV Bottle 5 mg/100 ml and Risedronate Tablet to Preferred status and Actonel and Calcitonin-Salmon Spray to Non-Preferred status. The Committee discussed safety concerns associated with Calcitonin-Salmon Spray and its place in therapy.
Botulinum Toxins	The Committee reviewed the Botulinum Toxins class and unanimously approved the following: moving Dysport to Preferred status.
Benign Prostatic Hyperplasia (BPH) Treatment	The Committee reviewed the Benign Prostatic Hyperplasia (BPH) Treatment class and unanimously approved the following: moving Dutasteride and Dutasteride-Tamsulosin to Non-Preferred status.
Calcium Channel Blockers	The Committee reviewed the Calcium Channel Blockers class and unanimously approved the following: moving Felodipine ER and Diltiazem ER Capsule 360 mg to Preferred status.
Cephalosporins and Related Antibiotics	The Committee reviewed the Cephalosporins and Related Antibiotics class and unanimously approved the following: moving Cefpodoxime Tablet to Preferred status.
Colony Stimulating Factors	The Committee reviewed the Colony Stimulating Factors class and unanimously approved no changes to the class. <u>Post Meeting Note:</u> Post meeting analysis identified Granix as an another cost effective option in this class. The Department recommended changing the status of Granix to Preferred.
Contraceptives, Oral	The Committee reviewed the Contraceptives, Oral class and unanimously approved the following: moving Low-Ogestrel 0.3-0.03, Norethin-Eth Estra-Ferrous Fum Chew 0.4-35(21), Ethynodiol-Ethinyl Estradiol 1-50, Wymza FE Chew, Microgestin 24 FE, Rajani, and Taytulla to Non-Preferred status and moving Larissia, Nortrel 1-35, Microgestin1-20, Microgestin 1.5-0.03, Enpresse, Alyacen 7 days x3, Nortrel 7 days x3, Pirmella 7 days x3, Aranelle 7-9-5, Leena 7-9-5, Natazia 3-2-1, Introvale 3 month, Quasense 3 month, Setlakin 3 month, Camrese 3 month, Jolivette, Nora-BE, Errin, Heather and Jencycla to Preferred status.
Contraceptives, Other	The Committee reviewed the Contraceptives, Other class and unanimously approved the following: moving Liletta, Skyla and Kyleena to Preferred status.

Epinephrine, Self-Injected	The Committee reviewed the Epinephrine, Self-Injected class and unanimously approved the following: changing brand EpiPen to Non-Preferred status. The generic epinephrine auto injector manufactured by Mylan is preferred.
Fluoroquinolones, Oral	The Committee reviewed the Fluoroquinolones, Oral class and unanimously approved no changes to the class.
Glucocorticoids, Oral	The Committee reviewed the Glucocorticoids, Oral class and unanimously approved the following: moving Dexamethasone Elixir to Preferred status.
Hepatitis B Agents	The Committee reviewed the Hepatitis B Agents class and unanimously approved the following: moving Lamivudine HBV to Preferred status and moving EpiVir HBV and Vemlidy to Non-Preferred status. The Committee discussed the current place in therapy of Vemlidy.
Hepatitis C Agents	The Committee reviewed the Hepatitis C Agents class and unanimously approved no changes to the class. Dr Cathers updated the Committee that Secretary Dallas accepted their recommendation to remove disease severity guideline (fibrosis score of F2-F4 or other risk factors) from the prior authorization guidelines. The recommendation will be phased-in with expansion to F1 in July 2017 and F0 in January 2018.
HIV/AIDS Medications	The Committee reviewed the HIV/AIDS Medications class and approved the following: moving Lopinavir-Ritonavir Solution, EpiVir, Ziagen, Abacavir-Lamivudine and Viramune Susp to Non-Preferred status and moving Lamivudine and Odefsey to Preferred status. The Committee discussed utilization of Non-preferred Triumeq. Triumeq is a complete regimen agent that contains three active ingredients and is taken as one tablet once daily. The same active ingredients in the same strengths are available as Epzicom, taken as one tablet once daily, in combination with Tivicay, taken as one tablet once daily. Epzicom and Tivicay are designated as Preferred agents.
Immunomodulators, Topical	The Committee reviewed the Immunomodulators, Topical class and unanimously approved the following: moving Imiquimod to Preferred status and moving Aldara to Non-Preferred status.
Intraarticular Hyaluronates	The Committee reviewed the Intraarticular Hyaluronates class and unanimously approved the following: adding Hyalgan and Hymovis to the PDL with a Preferred status and adding Gel-One, Euflexxa, Gelsyn-3, Supartz FX, Monovisc, Genvisc 850, Synvisc-One, Synvisc and Orthovisc to the PDL with a Non-Preferred status. This is a new class to the PDL.
Iron, Oral	The Committee reviewed the Iron, Oral class and unanimously approved the following: moving Hemocyte Plus, Tandem Dual Action, Integra, Integra Plus, Tandem Plus, Centrutex, Hemocyte-F, Wee Care Susp, Tricon, EZFE 200, Trigels-F Forte, Hematogen Forte, Folivane-F, Hematogen, Ferrocite Plus, TL Icon, Ferralet 90, and Duofer to Preferred status and moving Ferrex, FE C and Multigen Plus to Non-Preferred status.
Iron, Parenteral	The Committee reviewed the Iron, Parenteral class and unanimously approved the following: moving Venofer to Preferred status.
Lipotropics, Other Than Statins	The Committee reviewed the Lipotropics, Other Than Statins class and approved the following: moving Fenofibrate Tablet to Preferred status and moving Niaspan ER, Ezetimibe and Trilipix to Non-Preferred status. The Committee discussed the place in therapy, efficacy and adverse effects of Niacin products.

Lipotropics, Statins	The Committee reviewed the Lipotropics, Statins class and unanimously approved the following: moving Crestor to Non-Preferred status and moving Rosuvastatin to Preferred status.
Macrolides	The Committee reviewed the Macrolides class and unanimously approved the following: moving Erythromycin-Ethylsuccinate Susp (labeler 62559 only) to Preferred status. This product represents a cost effective Erythromycin option for the Department.
Neuropathic Pain Agents	The Committee reviewed the Neuropathic Pain Agents class and unanimously approved no changes to the class.
NSAIDs	The Committee reviewed the NSAIDs class and unanimously approved the following: moving Diclofenac Sodium Drops to Non-Preferred status.
Oncology Agents, Breast Cancer	The Committee reviewed the Oncology Agents, Breast Cancer class and unanimously approved no changes to this class.
Oncology Agents, Oral	The Committee reviewed the Oncology Agents, Oral class and unanimously approved no changes to this class.
Pituitary Suppressive Agents, LHRH	The Committee reviewed the Pituitary Suppressive Agents, LHRH class and unanimously approved the following: moving Vantas, Zoladex, Eligard and Trelstar to Preferred status, moving Leuprolide (labelers 00781 and 47335) to Non-Preferred status and leaving Leuprolide (labeler 00703 only) at Preferred status.
Prenatal Vitamins	The Committee reviewed the Prenatal Vitamins class and approved the following: moving Zatean-PN Plus, Taron-Prex, Zatean-PN DHA, Folivane-OB, Taron-C DHA, Niva-Plus, Triveen-Duo DHA, Completenate Chew, Ultimatecare One, Virtprex, Vol-Nate, PNV 29-1 and Focalgin CA to Preferred status and moving OB Complete Gold to Non-Preferred status.
Steroids, Topical	The Committee reviewed the Steroids, Topical class and unanimously approved the following: moving Clobetasol Foam to Preferred status and moving Olux Foam to Non-Preferred status.
Tetracyclines	The Committee reviewed the Tetracyclines class and unanimously approved the following: moving Doxycycline Hyclate Capsules and Tablets to Preferred status.
Vasodilators, Coronary	The Committee reviewed the Vasodilators, Coronary class and unanimously approved the following: moving Nitroglycerin Sublingual Tablets to Preferred status.
"No Change Drug Classes"	The Committee unanimously approved making no changes to the following classes: <ul style="list-style-type: none"> • Analgesics, Non-Opioid Barbiturate Combinations • Antibiotics, GI and Related Agents • Antibiotics, Inhaled – Cystic Fibrosis • Antibiotics, Topical • Antifungals, Oral • Antihypertensives, Sympatholytic • Antimigraine Agents, Other • Antipsoriatics, Oral

	<ul style="list-style-type: none"> • Antivirals, Topical • Bile Salts • Emollients • Enzyme Replacement, Gauchers Disease • Erythropoiesis Stimulating Proteins • Hereditary Angioedema (HAE) Agents • Idiopathic Pulmonary Fibrosis Agents • Immunomodulators, Atopic Dermatitis • Immunosuppressives, Oral • Nitrofurantoin Derivatives • Skeletal Muscle Relaxants • Thalidomide and Derivatives • Thyroid Hormones
Other Business	Dr. Gene Bishop announced she is resigning from her position on the Committee as she is no longer practicing medicine and seeing patients. Committee members expressed their appreciation for her many years of service.
Meeting Adjourned	Dr. Cathers thanked the Committee for their participation and adjourned the meeting.